Changes

==<u>Will your patent survive Bilski?==An Dolcera has conducted an in-depth analysis for on In Re Bilski's impact on software, medical devices and pharma method patents<br><br></u>.The USPTO is on the offensive since the In re Bilski verdict from the CAFC. Software companies have reported sharply higher rejection-rate from the patent office, and thousands of business method and software patents risk being invalidated because of this ruling.<br><br>We have conducted an analysis of hundreds of USPTO examination reports for method patents in three areas: a. Software, b. Medical device and diagnostic, and c. Pharmaceutical. We have now established the following: